BioSpace News Archive

Biotricity Inc. reported that it reached a record $13 million annualized revenue run rate in April -- further extending its growth by over eight percent from the $12 million run rate it announced for March 2023.

IRLAB Therapeutics AB announced the signing of an agreement, with the McQuade Center for Strategic Research and Development, LLC, for MSRD to evaluate the neuropsychiatric compounds IRL757 and IRL942 under exclusivity.

Sun Genomics continues to strategically expand its brand and clinical offerings with the appointment of Will Hankee as vice president of sales and business development.

Phio Pharmaceuticals Corp. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to proceed with a clinical trial of Phio’s lead product candidate, PH-762.

In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpoint, estimated glomerular filtration rate, with a p value < 0.0001.

ONWARD Medical N.V., the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury, provided a first quarter 2023 business update.

Royal Philips, provides an update on the comprehensive test and research program of its subsidiary Philips Respironics to assess potential health risks related to the polyester-based polyurethane sound abatement foam in specific sleep therapy and ventilator devices under the voluntary June 2021 recall notification/field safety notice.*

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced first quarter results which ended March 31, 2023 and provided a corporate update.

MindBio Therapeutics Corp. today issued a letter to shareholders from Justin Hanka, Co-Founder and Chief Executive Officer of MindBio.

Drug Farm, a private biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has raised the first round of C series financing totaling $27 million USD.